You just read:

Now Enrolling: Global Phase 3 Clinical Trial to Evaluate Potential First-Line Use of Lenvatinib in Combination with Pembrolizumab or Everolimus for Patients with Advanced Renal Cell Carcinoma

News provided by

Eisai Inc.

Sep 29, 2016, 07:30 ET